FIM-A, a phosphorus-containing sirolimus, inhibits the angiogenesis and proliferation of osteosarcomas

Oncology Research

Volumn 20, Issue 7, 2013, Pages 319-326

  Liu, Wei Nan ^a   Lin, Jian Hua ^a   Cheng, Yuan Rong ^b   Zhang, Li ^c   Huang, Jie ^b   Wu, Zhao Yang ^a   Wang, Fa Sheng ^a   Xu, Sheng Gui ^a,d   Lin, Wen Ping ^a   Lan, Wen Bin ^a   Yang, Guo Xin ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN INSTITUTE OF MICROBIOLOGY   (China)

^c FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Central Laboratory Mindong Hospital of Ningde City   (China)

Author keywords

Antiangiogenesis; Antiproliferation; FIM A; MTOR; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; FIM A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHORUS DERIVATIVE; RAPAMYCIN DERIVATIVE; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84878947516     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13644751511888     Document Type: Article

References (37)

1. Unni, K. K.; Inwards, C. Y. Dahlin's bone tumors: General aspects and data on 10,165 cases. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
2. Chandhanayingyong, C.; Kim, Y.; Staples, J. R.; Hahn, C.; Lee, F. Y. Mapk/erk signaling in osteosarcomas, ewing sarcomas and chondrosarcomas: Therapeutic implications and future directions. Sarcoma 2012:1-8; 2012.
3. Kempf-Bielack, B.; Bielack, S. S.; Jürgens, H.; Branscheid, D.; Berdel, W. E.; Exner, G. U.; Göbel, U.; Helmke, K.; Jundt, G.; Kabisch, H. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the cooperative osteosarcoma study group (coss). J. Clin. Oncol. 23:559-568; 2005.
4. Efeyan, A.; Sabatini, D. M. Mtor and cancer: Many loops in one pathway. Curr. Opin. Cell Biol. 22:169-176; 2010.
5. Zoncu, R.; Efeyan, A.; Sabatini, D. M. Mtor: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21-35; 2010.
6. Rajani, R.; Gibbs, C. P. Treatment of bone tumors. Surg. Pathol. Clin. 5:301-318; 2012.
7. Blay, J. Y. Updating progress in sarcoma therapy with mtor inhibitors. Ann. Oncol. 22:280-287; 2011.
8. Phang, J. M.; Liu, W.; Zabirnyk, O. Proline metabolism and microenvironmental stress. Annu. Rev. Nutr. 30:441-463; 2010.
9. Vemulapalli, S.; Mita, A.; Alvarado, Y.; Sankhala, K.; Mita, M. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target Oncol. 6:29-39; 2011.
10. Huang, J.;Yang, G. X.; Yu, H; Chen, X. Q.; Jing, D. W.; Cheng, Y. R. Sirolimus f904 and its derivative fim-a (ap23573) anticancer activity in vitro. J. Fujian Normal Univ. (Nat. Sci. Ed.) 26:63-66; 2010.
11. Luu, H. H.; Kang, Q.; Park, J. K.; Si, W.; Luo, Q.; Jiang, W.; Yin, H.; Montag, A. G.; Simon, M. A.; Peabody, T. D.; Haydon, R. C.; Rinker-Schaeffer, C. W.; He, T. C. An orthotopic model of human osteosarcoma growth and spontaneous pulmo-nary metastasis. Clin. Exp. Metastasis 22:319-329; 2005.
12. Dass, C. R.; Ek, E. T.; Contreras, K. G.; Choong, P. F. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin. Exp. Metastasis 23:367-380; 2006.
13. Berlin, O.; Samid, D.; Donthineni-Rao, R.; Akeson, W.; Amiel, D.; Woods, Jr., V. L. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res. 53:4890-4895; 1993.
14. Casanova, M.; Ferrari, A. Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opin. Pharmacother. 12:517-531; 2011.
15. Hashemolhosseini, S.; Nagamine, Y.; Morley, S. J.; Desrivières, S.; Mercep, L.; Ferrari, S. Rapamycin inhibition of the g1 to s transition is mediated by effects on cyclin d1 mrna and protein stability. J. Biol. Chem. 273:14424-14429; 1998.
16. Rosenwald, I. B.; Kaspar, R.; Rousseau, D.; Gehrke, L.; Leboulch, P.; Chen, J. J.; Schmidt, E. V.; Sonenberg, N.; London, I. M. Eukaryotic translation initiation factor 4e regulates expression of cyclin d1 at transcriptional and post- transcriptional levels. J. Biol. Chem. 270:21176-21180; 1995.
17. Rivera, V. M.; Squillace, R. M.; Miller, D.; Berk, L.; Wardwell, S. D.; Ning, Y.; Pollock, R.; Narasimhan, N. I.; Iuliucci, J. D.; Wang, F. Ridaforolimus (ap23573; mk-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol. Cancer Ther. 10:1059; 2011.
18. Gazitt, Y.; Kolaparthi, V.; Moncada, K.; Thomas, C.; Freeman, J. Targeted therapy of human osteosarcoma with 17aag or rapamycin: Characterization of induced apoptosis and inhibition of mtor and akt/mapk/wnt pathways. Int. J. Oncol. 34:551-561; 2009.
19. Lee, D. F.; Kuo, H. P.; Chen, C. T.; Hsu, J. M.; Chou, C. K.; Wei, Y.; Sun, H. L.; Li, L. Y.; Ping, B.; Huang, W. C.; He, X.; Hung, J. Y.; Lai, C. C.; Ding, Q.; Su, J. L.; Yang, J. Y.; Sahin, A. A.; Hortobagyi, G. N.; Tsai, F. J.; Tsai, C. H.; Hung, M. C. Ikk β suppression of tsc1 links inflammation and tumor angiogenesis via the mtor pathway. Cell 130:440-455; 2007.
20. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C. J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K. W.; Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 8:128-135; 2002.
21. Hay, N.; Sonenberg, N. Upstream and downstream of mtor. Genes Dev. 18:1926-1945; 2004.
22. Bjornsti, M. A.; Houghton, P. J. The tor pathway: A target for cancer therapy. Nat. Rev Cancer 4:335-348; 2004.
23. Guertin, D. A.; Sabatini, D. M. Defining the role of mtor in cancer. Cancer Cell 12:9-22; 2007.
24. Sabatini, D. M. Mtor and cancer: Insights into a complex relationship. Nat. Rev. Cancer 6:729-734; 2006.
25. Guertin, D. A.; Sabatini, D. M. The pharmacology of mtor inhibition. Sci. Signal. 2:pe24; 2009.
26. Corradetti, M.; Guan, K. Upstream of the mammalian target of rapamycin: Do all roads pass through mtor? Oncogene 25:6347-6360; 2006.
27. Ma, X. M.; Blenis, J. Molecular mechanisms of mtor-mediated translational control. Nat. Rev. Mol. Cell Biol. 10:307-318; 2009.
28. Eccles, S. A. Heparanase: Breaking down barriers in tumors. Nat. Med. 5:735-736; 1999.
29. Semenza, G. L. Regulation of mammalian o2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15:551-578; 1999.
30. Hirota, K.; Semenza, G. L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59:15-26; 2006.
31. Wan, X.; Shen, N.; Mendoza, A.; Khanna, C.; Helman, L. J. Cci-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mtor/hif-1a /vegf signaling. Neoplasia 8:394-401; 2006.
32. Mabuchi, S.; Altomare, D. A.; Connolly, D. C.; Klein-Szanto, A.; Litwin, S.; Hoelzle, M. K.; Hensley, H. H.; Hamilton, T. C.; Testa, J. R. Rad001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 67:2408-2413; 2007.
33. Phung, T. L.; Ziv, K.; Dabydeen, D.; Eyiah-Mensah, G.; Riveros, M.; Perruzzi, C.; Sun, J.; Monahan-Earley, R. A.; Shiojima, I.; Nagy, J. A.; Lin, M. I.; Walsh, K.; Dvorak, A. M.; Briscoe, D. M.; Neeman, M.; Sessa, W. C.; Dvorak, H. F.; Benjamin, L. E. Pathological angiogenesis is induced by sustained akt signaling and inhibited by rapamycin. Cancer Cell 10:159-170; 2006.
34. Mita, M. M.; Mita, A. C.; Chu, Q. S.; Rowinsky, E. K.; Fetterly, G. J.; Goldston, M.; Patnaik, A.; Mathews, L.; Ricart, A. D.; Mays, T.; Knowles, H.; Rivera, V. M.; Kreisberg, J.; Bedrosian, C. L.; Tolcher, A. W. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (ap23573; mk-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26:361-367; 2008.
35. Colombo, N.; McMeekin, S.; Schwartz, P.; Kostka, J.; Sessa, C.; Gehrig, P.; Holloway, R.; Braly, P.; Matei, D.; Einstein, M. A phase II trial of the mtor inhibitor ap23573 as a single agent in advanced endometrial cancer. J. Clin. Oncol. 25(Suppl.):278s; 2007.
36. Chawla, S.; Tolcher, A.; Staddon, A.; Schuetze, S.; D'Amato, G.; Blay, J.; Sankhala, K.; Daly, S.; Rivera, V.; Demetri, G. Updated results of a phase II trial of ap23573, a novel mtor inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J. Clin. Oncol. 24:9505a; 2006.
37. Hashemolhosseini, S.; Nagamine, Y.; Morley, S. J.; Desrivieres, S.; Mercep, L.; Ferrari, S. Rapamycin inhibition of the g1 to s transition is mediated by effects on cyclin d1 mrna and protein stability. J. Biol. Chem. 273:14424-14429; 1998.